Circassia appoints Stewart Sharpe as VP Commercial Operations
pharmafile | September 19, 2012 | Appointment | Medical Communications, Research and Development, Sales and Marketing | Circassia, Stewart Sharpe
Speciality biopharma firm Circassia has announced the appointment of Stewart Sharpe to the newly-created position of vice president, Commercial Operations.
Sharpe, who has extensive experience of leading multinational product launches, will lead Circassia’s preparations to commercialise its lead allergy programme.
Sharpe brings 25 years of commercial and marketing experience to Circassia. Most recently he was head of Commercial & Business Development at Astellas Pharma’s subsidiary OSI / Prosidion.
Previously, he held senior leadership roles at Takeda, Johnson & Johnson, Novartis, Roche and Glaxo Wellcome. During his career he has led the commercial activities for a number of new products, including the global launch of Xolair for Novartis.
Commenting on the appointment, Steve Harris, Circassia’s chief executive, said: “I am delighted to welcome Stewart to Circassia at this exciting time in the company’s development. Stewart brings to Circassia the senior-level experience and track record of achievement needed to help us achieve this ambitious goal, and we look forward to him leading our commercial preparations as we progress our novel cat allergy treatment to the marketplace.”
Related Content

Circassia terminates AstraZeneca partnership in exchange for £150m debt settlement
Circassia Pharmaceuticals has announced its decision to break away from a partnership it forged with …

Circassia stumbles with allergy treatments at clinical trial stage, again
Circassia has slumped at the Phase 2 clinical trial stage again, after its failure with …
Circassia raises funds to develop allergy products
UK biopharma company Circassia has raised £60 million funding for the final stage of development …






